Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
bluebird bio is hitting back at Spark Therapeutics over the use of the word “spark” involving the company’s “Be the Spark” campaign against sickle cell disease.
The vaccine, mRNA-1010, targets lineages recommended by the World Health Organization.
This morning, multiple companies announced clinical and strategic collaborations to develop novel therapies and treatments for various diseases. Here are some of them.
Perseverance is the foundation of impactful scientific discoveries, and is a core value that Precision BioSciences’ newly-appointed chief medical officer, oncology giant Alan List, shares.
This appears to be a second example of CRISPR gene editing inside the body, as opposed to in cell cultures.
The long weekend didn’t slow down the IPO train barreling down the tracks. More life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers.
Arbutus Biopharma forged a clinical collaboration with U.K.-based Vaccitech plc to develop a new treatment for people infected with chronic hepatitis B virus who are already receiving standard-of--care therapy.
Jardiance most recently received approval by the European Commission for the treatment of adult patients with HF with ejection fraction, based on findings from the EMPEROR-Reduced trial.
The expanded approval was made based on positive data from a second interim analysis of the Phase II KEYNOTE-629 trial.
Continuing studies and news about COVID-19 around the world keeps coming in. Here’s a look.
The two antibody candidates, AL001 and AL101, are seen as potential first-in-class medications aimed at a range of neurodegenerative diseases.
Upon completion of the merger, Parexel will be owned by EQT IX Fund and the private equity business within Goldman Sachs Asset Management.